Halozyme Therapeutics Inc

HALO

Company Profile

  • Business description

    Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.

  • Contact

    12390 El Camino Real
    San DiegoCA92130
    USA

    T: +1 858 794-8889

    E: [email protected]

    https://www.halozyme.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    423

Stocks News & Analysis

stocks

Major ASX miner reduces aluminium exposure

The Alcoa transaction unlocks value and sharpens ASX miners focus on base metals.
stocks

Vegemite owner’s shares remain expensive on normalising profits.

Australian dairy staple to see profits normalise with shares screening as overvalued.
stocks

Ask the analyst: Where does GYG stand following its US exit?

All roads lead back home for Guzman Y Gomez.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,037.0011.200.12%
CAC 408,479.8728.20-0.33%
DAX 4025,817.8938.580.15%
Dow JONES (US)52,948.7648.690.09%
FTSE 10010,651.7727.26-0.26%
HKSE23,616.32266.291.14%
NASDAQ26,128.18295.511.14%
Nikkei 22569,737.696.38-0.01%
NZX 50 Index13,763.10144.681.06%
S&P 5007,534.4551.210.68%
S&P/ASX 2008,831.0012.700.14%
SSE Composite Index4,041.242.41-0.06%

Market Movers